haematological cancer
MSD and Moderna announce potential new vaccine for melanoma
The mRNA-based therapy, used with Keytruda, is designed specifically for each patient
BMS’ Opdivo gets expanded FDA and EU approval for Hodgkin lymphoma
This type of cancer is the most common one diagnosed in teenagers
Gilead’s Trodelvy plus Keytruda shows positive results in metastatic breast cancer
The combination treatment showed a 35% reduction in the risk of disease progression
MSD receives NICE recommendation for Keytruda in advanced endometrial cancer
More than 9,700 new cases of endometrial cancer are diagnosed every year in the UK
Merck’s perioperative Keytruda regimen approved by FDA for head and neck cancer
More than 72,680 new cases of the disease are expected to be diagnosed in the US this year
Merck shares promising phase 3 results for Keytruda in ovarian cancer
Approximately 20,890 cases of the disease are expected to be diagnosed in the US this year
Bristol Myers Squibb’s perioperative Opdivo regimen granted EC approval in NSCLC
Up to 55% of patients with non-metastatic NSCLC develop recurrence despite curative resection
Bristol Myers Squibb’s injectable Opdivo formulation granted MHRA for solid tumours
The new formulation reduces administration time from 30-to-60 minutes to three-to-five minutes
Gilead shares promising phase 3 results for Trodelvy plus Keytruda in aggressive breast cancer
Triple-negative breast cancer accounts for approximately 15% of all cases of the disease
BMS receives NICE recommendation for immunotherapy combination in colorectal cancer
Approximately 44,000 people are diagnosed with colorectal cancer in the UK every year
BMS receives FDA approval for immunotherapy combination in liver cancer
Around 42,240 people are expected to be diagnosed with liver cancer in the US this year
BMS granted FDA approval for immunotherapy combination in colorectal cancer
More than 154,000 cases of the disease are expected to be diagnosed in the US this year